ZA909853B - Activatable fibrinolytic and anti-thrombotic proteins - Google Patents

Activatable fibrinolytic and anti-thrombotic proteins

Info

Publication number
ZA909853B
ZA909853B ZA909853A ZA909853A ZA909853B ZA 909853 B ZA909853 B ZA 909853B ZA 909853 A ZA909853 A ZA 909853A ZA 909853 A ZA909853 A ZA 909853A ZA 909853 B ZA909853 B ZA 909853B
Authority
ZA
South Africa
Prior art keywords
pct
fibrinolytic
activatable
clot formation
date jun
Prior art date
Application number
ZA909853A
Other languages
English (en)
Inventor
Keith Martyn Dawson
Martyn Dawson Keith
Richard Mark Edwards
Mark Edwards Richard
Joan Mabel Forman-Nee-Devine
Mabel Forman Nee Devine Joan
Original Assignee
British Bio Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio Technology filed Critical British Bio Technology
Publication of ZA909853B publication Critical patent/ZA909853B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C12N2830/704—S. cerevisiae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/107—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translational read-through

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA909853A 1989-12-07 1990-12-07 Activatable fibrinolytic and anti-thrombotic proteins ZA909853B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898927722A GB8927722D0 (en) 1989-12-07 1989-12-07 Proteins and nucleic acids

Publications (1)

Publication Number Publication Date
ZA909853B true ZA909853B (en) 1992-08-26

Family

ID=10667597

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA909853A ZA909853B (en) 1989-12-07 1990-12-07 Activatable fibrinolytic and anti-thrombotic proteins
ZA909854A ZA909854B (en) 1989-12-07 1990-12-07 Proteins and nucleic acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA909854A ZA909854B (en) 1989-12-07 1990-12-07 Proteins and nucleic acids

Country Status (21)

Country Link
US (2) US5434073A (fr)
EP (2) EP0502968B1 (fr)
JP (2) JPH05502374A (fr)
KR (2) KR920703818A (fr)
AT (1) ATE155812T1 (fr)
AU (3) AU644399B2 (fr)
CA (2) CA2069085C (fr)
DE (1) DE69031127T2 (fr)
DK (1) DK0502968T3 (fr)
ES (1) ES2106073T3 (fr)
FI (2) FI922609A0 (fr)
GB (1) GB8927722D0 (fr)
GR (1) GR3024990T3 (fr)
HU (1) HU211628A9 (fr)
IE (2) IE904416A1 (fr)
IL (2) IL96601A (fr)
NO (2) NO922237L (fr)
NZ (2) NZ236330A (fr)
PT (2) PT96103B (fr)
WO (2) WO1991009118A2 (fr)
ZA (2) ZA909853B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22277A1 (es) * 1990-05-23 1995-01-31 Cigb Procedimiento para el aislamiento y expresion de un gen codificante para estreptoquinasa,secuencia nucleotidica obtenida,adn recombinantes y microorganismos transformados
GB9222758D0 (en) * 1992-10-29 1992-12-09 British Bio Technology Proteins and nucleic acids
GB9216558D0 (en) * 1992-08-04 1992-09-16 British Bio Technology Modified proteases
GB2286190B (en) * 1992-10-29 1996-05-01 British Biotech Pharm Thrombin activatable plasminogen derivatives
DE4323754C1 (de) * 1993-07-15 1994-12-01 Gruenenthal Gmbh Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung
NZ271088A (en) * 1993-08-04 1996-10-28 Ciba Geigy Ag Desulphatohirudin muteins, their production, conjugates thereof and pharmaceutical compositions
ES2080657B1 (es) * 1993-09-27 1996-11-01 Britisch Bio Technology Limite Proteasas modificadas.
CZ312296A3 (en) * 1994-04-26 1997-05-14 Childrens Medical Center Angiostatin and its application for angiogenesis inhibition
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5945403A (en) 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
DE4440892A1 (de) * 1994-11-17 1996-05-23 Gruenenthal Gmbh Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften
DE4442665A1 (de) * 1994-11-30 1996-06-05 Gruenenthal Gmbh Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften
US5854049A (en) * 1995-06-09 1998-12-29 President And Fellows Of Harvard College Plasmin-resistant streptokinase
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US6461640B1 (en) 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
BR9711015A (pt) * 1996-08-02 1999-08-17 Boehringer Mannheim Gmbh Ativador de plasminog-nio capaz de ser ativado por trombina
EP1724282B1 (fr) * 1997-05-21 2013-05-15 Merck Patent GmbH Procédé de production de protéines non-immunogènes
ES2162361T3 (es) 1998-03-19 2001-12-16 Instrumentation Lab Spa Metodos, kits y reactivos mejorados para el muestreo de defectos de la coagulacion sanguinea.
US6365364B1 (en) 1998-08-20 2002-04-02 University Of Vermont And State Agriculture College Angiogenesis inhibitors and uses thereof
IN190822B (fr) * 1998-12-24 2003-08-23 Council Scient Ind Res
WO2001036351A2 (fr) 1999-11-19 2001-05-25 Corvas International, Inc. Antagonistes de l'inhibiteur des activateurs du plasminogène
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
AU2001285919B2 (en) * 2000-09-05 2007-08-23 Jiangsu Simcere Pharmaceutical R&D Co., Ltd Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
DE10108100A1 (de) * 2001-02-20 2002-08-29 Aventis Pharma Gmbh Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) * 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10108212A1 (de) * 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
DE10108211A1 (de) * 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
CN101044154A (zh) * 2002-02-14 2007-09-26 威廉·J·鲁特 治疗宿主中切割的嵌合分子
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (fr) 2006-06-14 2007-12-19 CSL Behring GmbH Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine
ES2889920T3 (es) 2006-06-14 2022-01-14 Csl Behring Gmbh Proteínas de fusión escindibles proteolíticamente con alta actividad específica molar
GB2455262A (en) * 2006-09-29 2009-06-10 Proteomtech Inc Methods for production of recombinant plasminogen and plasmin polypeptides
CN1970574B (zh) * 2006-12-08 2010-08-25 中国药科大学 溶栓和抗凝双重功效融合蛋白、制备方法及其应用
EP3231440A1 (fr) 2006-12-22 2017-10-18 CSL Behring GmbH Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
US20110262466A1 (en) * 2008-10-16 2011-10-27 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
SG2014012918A (en) 2009-02-11 2014-04-28 Novozymes Biopharma Dk As Albumin variants and conjugates
JP2012533560A (ja) * 2009-07-15 2012-12-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞における取り込みが制御可能なペプチド
CN105567699A (zh) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
KR20130099027A (ko) * 2010-08-05 2013-09-05 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 혈전용해 및 응고억제 특성을 갖는 단백질 융합 구조물
CN103874512B (zh) 2011-07-29 2016-11-16 艾维拉斯生物科学公司 选择性递送分子及使用方法
RU2604810C2 (ru) 2011-08-12 2016-12-10 Тромбодженикс Н.В. Варианты плазминогена и плазмина
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
EP3330283A3 (fr) 2012-03-16 2018-07-11 Albumedix A/S Variants d'albumine
US20140128326A1 (en) 2012-11-08 2014-05-08 Novozymes Biopharma Dk A/S Albumin variants
WO2014120837A2 (fr) 2013-01-29 2014-08-07 The Regents Of The University Of California Peptide à pénétration cellulaire activable pré-ciblé comportant un promédicament à libération intracellulaire
CN105102484B (zh) 2013-01-30 2020-03-10 艾维拉斯生物科学公司 选择性递送分子及使用方法
KR20150118123A (ko) 2013-02-16 2015-10-21 노보자임스 바이오파마 디케이 에이/에스 약동학적 동물 모델
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
CA2989966C (fr) 2015-08-20 2024-04-30 Albumedix A/S Variants de l'albumine et leurs conjugues

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1897087A (en) * 1927-12-14 1933-02-14 Tamarin Bernard Jacques Vacuum cleaner cord control device
US3608333A (en) * 1968-06-20 1971-09-28 Bison Mfg Co Inc Vacuum cleaner and power unit
US4880776A (en) * 1983-12-24 1989-11-14 Beecham Group P.L.C. Plasmin A-chain urokinase B-chain hybrid protein
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
DE3410437A1 (de) * 1984-03-22 1985-09-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von proteinen
GB8412517D0 (en) * 1984-05-16 1984-06-20 Nagai K Recombinant fusion proteins
US5087564A (en) * 1985-06-20 1992-02-11 Monsanto Company Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3523701A1 (de) * 1985-07-03 1987-01-08 Bayer Ag Verfahren zur herstellung von proteinen und polypeptiden
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
FI882407A (fi) * 1987-05-22 1988-11-23 Zymogenetics Inc Fibrinolytiska proteiner.
US5200340A (en) * 1987-05-22 1993-04-06 Zymogenetics, Inc. Thrombin-activated tissue plasminogen activators
FI882746A (fi) * 1987-06-12 1988-12-13 Hoechst Japan Hybridprotein c och foerfarande foer dess framstaellning.
EP0297882B1 (fr) * 1987-07-01 1993-08-25 Beecham Group Plc Activateurs de plasminogène hybrides
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1340802C (fr) * 1987-08-15 1999-10-26 Yasuyuki Takahashi Proteine precurseur de l'amyloide senile et anticorps specifique pour cette proteine
EP0330700B1 (fr) * 1987-08-19 1993-12-22 Sagami Chemical Research Center Polypeptide ressemblant à la prourokinase humaine
CA1340740C (fr) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Coexpressiondans des cellules eucaryotes
CA1340877C (fr) * 1987-12-28 2000-01-18 Takashi Sugiyama Polypeptide inhibant l'elastage et procede de production par la technologie de l'adn recombinant
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
GB8809129D0 (en) * 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
KR920701459A (ko) * 1989-02-17 1992-08-11 코돈 트롬보모듈린의 가용성 유사체
AU647391B2 (en) * 1989-05-01 1994-03-24 University Of Notre Dame Du Lac, The Methods and materials for expression of human plasminogen in a eukaryotic cell system
US5164304A (en) * 1989-05-04 1992-11-17 Sri International Method and vectors for stabilizing hirudin and human laminin b1 expression
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
ATE181108T1 (de) * 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus

Also Published As

Publication number Publication date
NZ236401A (en) 1992-03-26
WO1991009118A3 (fr) 1991-10-31
NO305562B1 (no) 1999-06-21
KR920703818A (ko) 1992-12-18
FI922610A0 (fi) 1992-06-05
AU643247B2 (en) 1993-11-11
EP0504241A1 (fr) 1992-09-23
AU6954091A (en) 1991-07-18
AU4497693A (en) 1993-11-18
IL96601A0 (en) 1991-09-16
EP0502968A1 (fr) 1992-09-16
EP0502968B1 (fr) 1997-07-23
GR3024990T3 (en) 1998-01-30
KR920703803A (ko) 1992-12-18
CA2069105A1 (fr) 1991-06-08
JP2851423B2 (ja) 1999-01-27
NO922238D0 (no) 1992-06-05
ES2106073T3 (es) 1997-11-01
PT96104A (pt) 1991-09-30
US5434073A (en) 1995-07-18
IE904417A1 (en) 1991-06-19
FI922610A (fi) 1992-06-05
AU6965691A (en) 1991-07-18
IE904416A1 (en) 1991-07-17
AU644399B2 (en) 1993-12-09
IL96602A0 (en) 1992-05-25
FI922609A (fi) 1992-06-05
DE69031127D1 (de) 1997-09-04
FI922609A0 (fi) 1992-06-05
FI105202B (fi) 2000-06-30
NZ236330A (en) 1993-05-26
PT96103A (pt) 1991-09-30
ZA909854B (en) 1992-08-26
JPH05502375A (ja) 1993-04-28
ATE155812T1 (de) 1997-08-15
KR100188302B1 (ko) 1999-06-01
HU211628A9 (en) 1995-12-28
JPH05502374A (ja) 1993-04-28
GB8927722D0 (en) 1990-02-07
DK0502968T3 (da) 1998-03-02
IL96601A (en) 1999-05-09
NO922238L (no) 1992-08-06
US5637492A (en) 1997-06-10
DE69031127T2 (de) 1998-02-05
WO1991009118A2 (fr) 1991-06-27
CA2069085A1 (fr) 1991-06-08
NO922237D0 (no) 1992-06-05
NO922237L (no) 1992-08-06
IE81046B1 (en) 1999-12-01
PT96103B (pt) 1998-08-31
CA2069085C (fr) 2000-02-01
WO1991009125A1 (fr) 1991-06-27

Similar Documents

Publication Publication Date Title
GR3024990T3 (en) Activatable fibrinolytic and anti-thrombotic proteins
Witting et al. Thrombin-specific inhibition by and slow cleavage of hirulog-1
Stocker et al. Thrombin-like snake venom proteinases
Lijnen et al. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones
ES2018729A6 (es) Un metodo para preparar una variante de activador de plasmogeno de tejido.
Gertler et al. Prothrombotic and fibrinolytic function of normal and perturbed endothelium
Pâques et al. Comparative study on the in vitro effectiveness of antithrombotic agents
Gasmi et al. Further characterization and thrombolytic activity in a rat model of a fibrinogenase from Vipera lebetina venom
Pirkle et al. Thrombin-like venom enzymes: structure and function
Saba et al. Effect of lysosomal cationic proteins from polymorphonuclear leukocytes upon the fibrinogen and fibrinolysis system
Daoud et al. Mechanism of the anticoagulant, Cerastase F-4, isolated from Cerastes cerastes (Egyptian sand viper) venom
EP0218479A3 (en) Reagent and process
Geratz et al. Current concepts on action of synthetic thrombin inhibitors
Paoni et al. Involvement of residues 296–299 in the enzymatic activity of tissue-type plasminogen activator
FI932196A (fi) Foerfarande foer bestaemning av fibrinogen
EP0326013A3 (fr) Protéines dérivées de l'inhibiteur de l'alpha-2-plasmine humaine ou protéines similaires à celles-ci
Klöcking et al. Effects of snake venoms on tissue-type plasminogen activator release
KLÖCKING et al. Recent Developments in Toxicology: Trends, Methods and Problems Arch. Toxicol., Suppl. 14, 157–159 (1991) Springer-Verlag 1991
Stief et al. Specificity of functional determination of urokinase in human plasma using selective oxidants
Gould et al. Design of antithrombotic agents: An introduction
Hanemaaijer et al. Inhibition of urokinase-type and tissue-type plasminogen activator—mediated plasminogen activation by doxycycline
Fenton Thrombin structural regions in determining bioregulatory functions
Cederholm-Williams Molecular mechanism of fibrinolysis and its potential role in metastasis
UA10374C2 (uk) Спосіб визhачеhhя вмісту фібриhогеhу в плазмі крові при гепариhотерапії